WHICH RISK-FACTORS PREDICT THE LEVODOPA RESPONSE IN FLUCTUATING PARKINSONS-DISEASE

被引:26
作者
HORSTINK, MWIM
ZIJLMANS, JCM
PASMAN, JW
BERGER, HJC
KORTEN, JJ
VANTHOF, MA
机构
[1] CATHOLIC UNIV NIJMEGEN,DEPT CLIN ELECTRONEUROPHYSIOL,6500 HB NIJMEGEN,NETHERLANDS
[2] MAASLAND ZIEKENHUIS,DEPT NEUROL,SITTARD,NETHERLANDS
[3] CATHOLIC UNIV NIJMEGEN,DEPT MED PSYCHOL,6500 HB NIJMEGEN,NETHERLANDS
[4] CATHOLIC UNIV NIJMEGEN,DEPT STAT CONSULTAT,6500 HB NIJMEGEN,NETHERLANDS
关键词
D O I
10.1002/ana.410270514
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Three putative risk factors to the pathogenesis of end‐of‐dose–related fluctuations–severity of Parkinson's disease (PD), duration of PD, and duration of levodopa therapy–were evaluated in 39 patients with PD by measuring response duration and response magnitude to a single levodopa dose. After discontinuing levodopa therapy for 12 hours, the motor status of each patient was assessed before a single dose of 100 mg of levodopa plus 25 mg of decarboxylase inhibitor was given and at five 45‐minute intervals thereafter. Multiple regression analysis showed that the response duration was best predicted by the severity of PD. The response magnitude was significantly correlated both to the duration of PD and to the duration of levodopa therapy. It is argued, however, that the response magnitude was predicted by the duration of levodopa therapy. Our results are in accordance with those of other recent studies and indicate that variances in levodopa response duration and in levodopa response magnitude are caused by their own differential risk factor. Copyright © 1990 American Neurological Association
引用
收藏
页码:537 / 543
页数:7
相关论文
共 33 条
  • [1] 6 YEARS OF HIGH-LEVEL LEVODOPA THERAPY IN SEVERELY AKINETIC PARKINSONIAN PATIENTS
    BARBEAU, A
    [J]. ARCHIVES OF NEUROLOGY, 1976, 33 (05) : 333 - 338
  • [2] DISTINCTION BETWEEN BENIGN AND MALIGNANT TYPE OF PARKINSONS-DISEASE
    BIRKMAYER, W
    RIEDERER, P
    YOUDIM, MBH
    [J]. CLINICAL NEUROLOGY AND NEUROSURGERY, 1979, 81 (03) : 158 - 164
  • [3] DOES LEVODOPA AGGRAVATE PARKINSONS-DISEASE
    BLIN, J
    BONNET, AM
    AGID, Y
    [J]. NEUROLOGY, 1988, 38 (09) : 1410 - 1416
  • [4] FACTORS THAT INFLUENCE THE OCCURRENCE OF RESPONSE VARIATIONS IN PARKINSONS-DISEASE
    DEJONG, GJ
    MEERWALDT, JD
    SCHMITZ, PIM
    [J]. ANNALS OF NEUROLOGY, 1987, 22 (01) : 4 - 7
  • [5] MULTICENTER STUDY OF PARKINSON MORTALITY WITH EARLY VERSUS LATER DOPA TREATMENT
    DIAMOND, SG
    MARKHAM, CH
    HOEHN, MM
    MCDOWELL, FH
    MUENTER, MD
    [J]. ANNALS OF NEUROLOGY, 1987, 22 (01) : 8 - 12
  • [6] TO TREAT EARLY OR TO TREAT LATE
    DUVOISIN, RC
    [J]. ANNALS OF NEUROLOGY, 1987, 22 (01) : 2 - 3
  • [7] MOTOR FLUCTUATIONS IN PARKINSONS-DISEASE - CENTRAL PATHOPHYSIOLOGICAL MECHANISMS .1.
    FABBRINI, G
    MOURADIAN, MM
    JUNCOS, JL
    SCHLEGEL, J
    MOHR, E
    CHASE, TN
    [J]. ANNALS OF NEUROLOGY, 1988, 24 (03) : 366 - 371
  • [8] SHOULD LEVODOPA THERAPY FOR PARKINSONISM BE STARTED EARLY OR LATE - EVIDENCE AGAINST EARLY TREATMENT
    FAHN, S
    BRESSMAN, SB
    [J]. CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1984, 11 (01) : 200 - 205
  • [9] ON-OFF FLUCTUATIONS IN PARKINSONS-DISEASE - A CLINICAL AND NEURO-PHARMACOLOGICAL STUDY
    HARDIE, RJ
    LEES, AJ
    STERN, GM
    [J]. BRAIN, 1984, 107 (JUN) : 487 - 506
  • [10] PARKINSONISM - ONSET PROGRESSION AND MORTALITY
    HOEHN, MM
    YAHR, MD
    [J]. NEUROLOGY, 1967, 17 (05) : 427 - &